JAK2-V617F mutation in cerebral venous thrombosis

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 6, 2009, Pages 1039-1040

  Koopman, Karen ^a   Mulder, A B ^a   De Keyser, J ^a,b   Luijckx, G J ^a   Van Der Meer, J ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ARTICLE; CEREBRAL SINUS THROMBOSIS; GENE FREQUENCY; GENE MUTATION; HEMATOPOIESIS; HUMAN; MUTATION RATE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SPLANCHNIC NERVE; SPLANCHNIC VEIN THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS;

BASE SEQUENCE; BRAIN; DNA PRIMERS; HUMANS; JANUS KINASE 2; MUTATION; VENOUS THROMBOSIS;

EID: 65849105761     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03354.x     Document Type: Article

References (17)

1. Bousser MG, Ferro JM. Cerebral venous thrombosis: An update. Lancet Neurol 2007; 6: 162-70.
2. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352: 1791-8.
3. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275-90.
4. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.
6. Austin SK, Lambert JR. The JAK2(V617F) mutation and thrombosis. Br J Haematol 2008; 143: 307-20.
7. Remacha AF, Estivill C, Sarda MP, Mateo J, Souto JC, Canals C, Nomdedeu J, Fontcuberta J. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 2007; 92: 285-6.
8. De Stefano V, Rossi E, Za T, Chiusolo P, Leone G. The JAK2 V617F mutation in patients with cerebral venous thrombosis: A rebuttal. Thromb Haemost 2008; 99: 1121.
9. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-14.
10. Colaizzo D, Amitrano L, Iannaccone L, Vergura P, Cappucci F, Grandone E, Guardascione MA, Margaglione M. Gain-of-function gene mutations and venous thromboembolism: Distinct roles in different clinical settings. J Med Genet 2007; 44: 412-16.
11. Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK, Tefferi A. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: Assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008; 83: 457-9.
12. Bellucci S, Cassinat B, Bonnin N, Marzac C, Crassard I. The V617F JAK. 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thromb Haemost 2008; 99: 1119-20.
13. Xavier SG, Gadelha T, Schaffel R, Britto L, Pimenta G, Ribeiro DD, Sabino Ade P, Pires V, Renault IZ, Spector N. Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis. Blood Coagul Fibrinolysis 2008; 19: 468-9.
14. Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx GJ. Development and validation of a predictive outcome score of cerebral venous thrombosis. J Neurol Sci 2009; 276: 66-8.
15. Poodt J, Fijnheer R, Walsh IB, Hermans MH. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. Hematol Oncol 2006; 24: 227-33.
16. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20: 471-6.
17. Ugo V, Le Gal G, Lecucq L, Mottier D, Oger E. Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. J Thromb Haemost 2008; 6: 203-5.